Kura Oncology (KURA) Stock Price, Quote & News

Company Profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC;...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 500 8800

Website: kuraoncology.com

Address:

12730 High Bluff Drive, Suite 400, San Diego, United States

They_call_me_tater_salad Aug. 22 at 6:01 PM

$KURA Have opened a small position to monitor this one. Expect to be in heavier in the months ahead.

0 · Reply

mark31 Aug. 22 at 2:13 PM

$CODI $KURA $PGEN

0 · Reply

mimiwor Aug. 22 at 2:10 PM

$CODI $KURA $PGEN

1 · Reply

Longterm007 Aug. 21 at 8:02 PM

$KURA Link?

1 · Reply

redistributeW Aug. 21 at 7:05 PM

$KURA KO 2086 and cabozantinib 2nd half 2025 readout

0 · Reply

Longterm007 Aug. 21 at 6:13 PM

$KURA Whats happing?????

1 · Reply

JD101 Aug. 21 at 5:54 PM

$KURA 👀 buyout ?

0 · Reply

JD101 Aug. 21 at 3:54 PM

$LIXT $GNLX $VVOS $KURA $PBM all monsters that I have chips in

2 · Reply

American12345 Aug. 21 at 2:15 PM

$KURA woah.😳

0 · Reply

lowfloatscambuster Aug. 20 at 8:00 PM

$KURA would be good to fill that gap @ $6.74. Will probably happen next few days. So far so good

1 · Reply

Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 15 days ago

Kura Oncology Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 7:30 AM EDT - 19 days ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 31, 2025, 7:30 AM EDT - 23 days ago

Kura Oncology to Report Second Quarter 2025 Financial Results

Jul 2, 2025, 12:09 AM EDT - 7 weeks ago

Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well

Jun 12, 2025, 7:30 AM EDT - 2 months ago

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

Jun 2, 2025, 6:00 PM EDT - 2 months ago

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

$Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML$

Jun 1, 2025, 7:00 PM EDT - 2 months ago

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

May 22, 2025, 5:30 PM EDT - 3 months ago

Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting

May 20, 2025, 7:30 AM EDT - 3 months ago

Kura Oncology to Participate in Three Upcoming Investor Conferences

May 14, 2025, 10:00 AM EDT - 3 months ago

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress

May 6, 2025, 7:30 AM EDT - 3 months ago

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

May 1, 2025, 8:48 PM EDT - 4 months ago

Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript

May 1, 2025, 4:05 PM EDT - 4 months ago

Kura Oncology Reports First Quarter 2025 Financial Results

Apr 28, 2025, 7:30 AM EDT - 4 months ago

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

Apr 24, 2025, 7:30 AM EDT - 4 months ago

Kura Oncology to Report First Quarter 2025 Financial Results

Apr 8, 2025, 7:30 AM EDT - 4 months ago

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

Apr 1, 2025, 7:30 AM EDT - 5 months ago

Kura Oncology to Participate in Stifel Targeted Oncology Forum

Mar 26, 2025, 7:30 AM EDT - 5 months ago

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

Mar 4, 2025, 10:12 AM EST - 6 months ago

Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity

Feb 27, 2025, 4:46 AM EST - 6 months ago

Kura Oncology, Inc. (KURA) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:03 PM EST - 6 months ago

Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 19, 2025, 7:30 AM EST - 6 months ago

Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results

Feb 6, 2025, 12:05 PM EST - 7 months ago

Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies

Feb 5, 2025, 4:01 PM EST - 7 months ago

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

Jan 6, 2025, 4:30 PM EST - 8 months ago

Kura Oncology Announces Senior Executive Promotions

Dec 18, 2024, 1:46 PM EST - 8 months ago

Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)

Dec 9, 2024, 7:00 AM EST - 9 months ago

Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

Dec 2, 2024, 7:30 AM EST - 9 months ago

Kura Oncology to Host Virtual Investor Event on December 9, 2024

Nov 25, 2024, 7:30 AM EST - 9 months ago

Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit

Nov 20, 2024, 5:52 PM EST - 9 months ago

Kura Oncology to partner with Kyowa Kirin for blood cancer therapy

Nov 20, 2024, 5:00 PM EST - 9 months ago

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

Nov 9, 2024, 5:54 AM EST - 10 months ago

Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 9:09 AM EST - 10 months ago

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting

Oct 31, 2024, 7:30 AM EDT - 10 months ago

Kura Oncology to Report Third Quarter 2024 Financial Results

Oct 29, 2024, 8:00 AM EDT - 10 months ago

Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

Oct 24, 2024, 7:30 AM EDT - 10 months ago

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)

Oct 23, 2024, 7:30 AM EDT - 10 months ago

Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors

Sep 30, 2024, 6:30 PM EDT - 11 months ago

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology

Sep 17, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

Aug 9, 2024, 2:07 PM EDT - 1 year ago

Kura Oncology, Inc. (KURA) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology to Report Second Quarter 2024 Financial Results

Jun 24, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes

Jun 11, 2024, 2:00 PM EDT - 1 year ago

Life Science Cares San Diego Teams with Kura Oncology to Support Nutritional Needs of the San Diego Community

May 29, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology to Participate in Jefferies Global Healthcare Conference

May 14, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

May 4, 2024, 5:28 PM EDT - 1 year ago

Kura Oncology, Inc. (KURA) Q1 2024 Earnings Call Transcript

May 2, 2024, 4:05 PM EDT - 1 year ago

Kura Oncology Reports First Quarter 2024 Financial Results

Apr 25, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology to Report First Quarter 2024 Financial Results

They_call_me_tater_salad Aug. 22 at 6:01 PM

$KURA Have opened a small position to monitor this one. Expect to be in heavier in the months ahead.

0 · Reply

mark31 Aug. 22 at 2:13 PM

$CODI $KURA $PGEN

0 · Reply

mimiwor Aug. 22 at 2:10 PM

$CODI $KURA $PGEN

1 · Reply

Longterm007 Aug. 21 at 8:02 PM

$KURA Link?

1 · Reply

redistributeW Aug. 21 at 7:05 PM

$KURA KO 2086 and cabozantinib 2nd half 2025 readout

0 · Reply

Longterm007 Aug. 21 at 6:13 PM

$KURA Whats happing?????

1 · Reply

JD101 Aug. 21 at 5:54 PM

$KURA 👀 buyout ?

0 · Reply

JD101 Aug. 21 at 3:54 PM

$LIXT $GNLX $VVOS $KURA $PBM all monsters that I have chips in

2 · Reply

American12345 Aug. 21 at 2:15 PM

$KURA woah.😳

0 · Reply

lowfloatscambuster Aug. 20 at 8:00 PM

$KURA would be good to fill that gap @ $6.74. Will probably happen next few days. So far so good

1 · Reply

elmono Aug. 19 at 3:17 PM

$XBI best small caps down 5%…XBI down only 1.3%….market manipulation. $LRMR $AQST $KURA $OLMA ….I hate this market so much 😁

1 · Reply

Whiskey1679 Aug. 18 at 8:10 PM

Whiskey's Picks out tomorrow by 6:20 am! Ill have 1 great pick!! Trending: $LIDR $AKBA $KURA $PPCB $PANW

0 · Reply

lowfloatscambuster Aug. 18 at 8:03 PM

$KURA For a stock that has acted so poorly for so long, this is quite a textbook consolidation thus far

0 · Reply

geffaxp Aug. 18 at 7:32 PM

$KURA BIOPHARMACEUTICALS ARE THE MOST LIKELY STOCKS TO EXPLODE WHEN THEY BEGIN TO USE A.I. TO FIND NEW CURES AND MEDICINES. $IBB IS ONE EXAMPLE OF AN ETF THAT COVERS MANY COMPANIES IN THE SECTOR. ALL YOU NEED IS ONE COMPANY TO FIND THE CURE FOR CANCER OR HERPES OR THE COMMON COLD OR SOME OF THE PREVIOUSLY UNKNOWN PATHOGENS BROUGHT ACROSS THE BORDER IN THE LAST 4 YEARS. A.I. WILL DISCOVER IN A FEW WEEKS WHAT USED TO TAKE YEARS AND DECADES. GO BIOTECH/BIOPHARMACEUTICALS YOUNG MAN OR WOMAN. YES, I KNOW. WHY DIDN'T I THINK OF THAT?

1 · Reply

mimiwor Aug. 18 at 6:14 PM

$KURA wish this pull back little bit.

1 · Reply

tltisbae Aug. 18 at 2:27 PM

$KURA so can we see $24?

1 · Reply

outlawinvestor1 Aug. 17 at 10:57 PM

$KURA always reassuring, when mgmt is buying alongside investors at the same price.

0 · Reply

lowfloatscambuster Aug. 15 at 9:02 PM

$KURA Everyone here should look at what they did to $TNXP today in the premarket session. Take notes

3 · Reply

ArbysRawMeats Aug. 15 at 6:17 PM

$KURA they hit the “make money” button

0 · Reply

BigJuicy Aug. 15 at 5:06 PM

$KURA up 40% in a week? Buyout coming?

3 · Reply

Gps_100X_ROI_Potential Aug. 15 at 4:08 PM

$SLS Couple of Considerations: Nice to See $SNDX and $KURA Climbing Again, Menin Inhibitors AML KMT2A, NMP Targeted Agents - some pressure from 2 other Menin inhibitors, bleximenib... - If anyone is interested in a Direct COMP for SLS009 at this stage of development - with a PIVOTAL / ie REGISTRATIONAL Trial on the board, look at Both Zifto and Revu /menib - when their P2 Pivotal Trials were about to Start. - Each Co was Worth More than A billion in Market cap. Just SLS009 Right now is worth 8 -10x the Current Manipulated Market Cap . . . Now YOU KNOW. Institutional Money will continue to buy in / they know / big pharma knows - SLS009 is the First Ever and ONLY highly Selective and Targeted CDKinase inhibitor to pass Key Safety Hurdles. B P has been testing CDK9's for years - they know.

1 · Reply

boomshiva Aug. 15 at 4:05 PM

$KURA I'm not complaining on the green. Just wish the stock had let me get a full position first.

1 · Reply

Market Cap	645.77M
Revenue (ttm)	53.88M
Net Income (ttm)	-173.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-322.90%
Debt to Equity Ratio	0.03

Volume	2,562,700
Avg Vol	1,548,418
Day's Range	N/A - N/A
Shares Out	86.80M
Stochastic %K	93%
Beta	0.41
Analysts	Strong Sell
Price Target	$25.42